Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial

Journal:

The Lancet Global Health

Published:

2025-09-18

DOI:

10.1016/s2214-109x(25)00272-4

Affiliations:

8

Authors:

36

Go to article

Institutions	Authors	Share
Kenya Medical Research Institute (KEMRI), Kenya	6.142857	0.26
Kwame Nkrumah University of Science and Technology (KNUST), Ghana	4.642857	0.19
Agogo Presbyterian Hospital, Ghana	4.642857	0.19
GlaxoSmithKline Belgium, Belgium	4.142857	0.17
PATH Center for Vaccine Innovation and Access, United States of America (USA)	2.142857	0.09
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), CDC, United States of America (USA)	1.642857	0.07
Centers for Disease Control and Prevention-Kenya (CDC-K), Kenya	0.642857	0.03

Interested in Medical Microbiology?